Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of Phase 3 study.
At the interim analysis, 7.3 percent of patients who received molnupiravir were hospitalized through day 29, compared with 14.1 percent of placebo-treated patients who were hospitalized or died
Merck plans to seek Emergency Use Authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide
If authorized, molnupiravir could be the first oral antiviral medicine for COVID-19
Read the full press release here.
Source : Merck
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Breakthrough COVID-19 does not meaningfully affect HIV CD4+ count
-
[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.